- Home
- MCO vs ZTS Comparison
MCO vs ZTS Comparison
Compare MCO & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCO
- ZTS
- Stock Information
- Founded
- MCO 1900
- ZTS 1952
- Country
- MCO United States
- ZTS United States
- Employees
- MCO N/A
- ZTS N/A
- Industry
- MCO Finance: Consumer Services
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- MCO Finance
- ZTS Health Care
- Exchange
- MCO Nasdaq
- ZTS Nasdaq
- Market Cap
- MCO 90.6B
- ZTS 80.4B
- IPO Year
- MCO 2000
- ZTS 2013
- Fundamental
- Price
- MCO $466.23
- ZTS $163.87
- Analyst Decision
- MCO Buy
- ZTS Strong Buy
- Analyst Count
- MCO 16
- ZTS 9
- Target Price
- MCO $500.27
- ZTS $220.33
- AVG Volume (30 Days)
- MCO 624.8K
- ZTS 2.6M
- Earning Date
- MCO 02-11-2025
- ZTS 02-11-2025
- Dividend Yield
- MCO 0.73%
- ZTS 1.05%
- EPS Growth
- MCO 33.08
- ZTS 8.38
- EPS
- MCO 10.94
- ZTS 5.32
- Revenue
- MCO $6,896,000,000.00
- ZTS $9,152,000,000.00
- Revenue This Year
- MCO $19.46
- ZTS $9.48
- Revenue Next Year
- MCO $6.62
- ZTS $4.92
- P/E Ratio
- MCO $42.64
- ZTS $31.00
- Revenue Growth
- MCO 20.43
- ZTS 9.33
- 52 Week Low
- MCO $360.05
- ZTS $144.80
- 52 Week High
- MCO $503.95
- ZTS $200.53
- Technical
- Relative Strength Index (RSI)
- MCO 37.00
- ZTS 29.38
- Support Level
- MCO $486.82
- ZTS $163.37
- Resistance Level
- MCO $488.95
- ZTS $181.85
- Average True Range (ATR)
- MCO 8.38
- ZTS 3.88
- MACD
- MCO -4.17
- ZTS -1.22
- Stochastic Oscillator
- MCO 17.25
- ZTS 5.06
About MCO Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and about half the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.